A MICROSIMULATION MODEL FOR HIGH-RISK STAGE II AND STAGE III COLON CANCER SURVIVORS FOLLOWING THE CURRENT GUIDELINES

被引：0
|
作者：
Samur, S. [1 ]
Gursel, E. [2 ,3 ]
Gu, N. Y.
Palomares, M. [3 ]
Sahinkoc, M. [4 ]
Hoban, O. [2 ]
Cuyun, Carter G. [3 ]
Ayer, T. [5 ]
Chhatwal, J. [4 ]
Parikh, A. [4 ]
Neugut, A., I [6 ]
机构：
[1] Value Analyt Labs, Chantilly, VA USA
[2] Value Analyt Labs, Boston, MA USA
[3] Exact Sci, Madison, WI USA
[4] Harvard Med Sch, Boston, MA USA
[5] Georgia Inst Technol, Atlanta, GA USA
[6] Columbia Univ, New York, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P59
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [31] Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer
    Wang, Liming
    Hirano, Yasumitsu
    Ishii, Toshimasa
    Kondo, Hiroka
    Hara, Kiyoka
    Obara, Nao
    Yamaguchi, Shigeki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [32] How to improve outcome in high-risk stage III colon cancer with dMMR gene
    Abdelsalam, Y.
    Elbaiomy, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S28 - S28
  • [33] High-risk groups of patients with stage II colon carcinoma
    Merkel, S
    Wein, A
    Günther, K
    Papadopoulos, T
    Hohenberger, W
    Hermanek, P
    CANCER, 2001, 92 (06) : 1435 - 1443
  • [34] Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease
    Hajirawala, Luv N.
    Yi, Yong
    Herritt, Brian C.
    Laurent, Morgan E.
    Klinger, Aaron L.
    Orangio, Guy R.
    Davis, Kurt G.
    Barton, Jeffrey S.
    DISEASES OF THE COLON & RECTUM, 2023, 66 (08) : 1076 - 1084
  • [35] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Zunder, Stephanie M.
    van Pelt, Gabi W.
    Gelderblom, Hans J.
    Mancao, Christoph
    Putter, Hein
    Tollenaar, Rob A.
    Mesker, Wilma E.
    BRITISH JOURNAL OF CANCER, 2018, 119 (02) : 164 - 169
  • [36] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Zunder, S.
    van Pelt, G.
    Gelderblom, H.
    Tollenaar, R.
    Mancao, C.
    Mesker, W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Stéphanie M. Zunder
    Gabi W. van Pelt
    Hans J. Gelderblom
    Christoph Mancao
    Hein Putter
    Rob A. Tollenaar
    Wilma E. Mesker
    British Journal of Cancer, 2018, 119 : 164 - 169
  • [38] Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features
    Cheong, C.
    Suh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] The Role of Anastomotic Leak as a Potential High-Risk Criteria in Stage II Colon Cancer
    Behman, Ramy
    Coburn, Natalie
    Ashamalla, Shady
    Perera, Sheron
    Mahar, Alyson
    Jeong, Irene
    Hallet, Julie
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S85 - S86
  • [40] Is Microsatellite Status Associated With Prognosis in Stage II Colon Cancer With High-Risk Features?
    Cavallaro, Paul M.
    Stafford, Caitlin
    Cauley, Christy E.
    Berger, David L.
    Bordeianou, Liliana
    Kunitake, Hiroko
    Francone, Todd
    Ricciardi, Rocco
    DISEASES OF THE COLON & RECTUM, 2021, 64 (05) : 545 - 554
12345